Howard Liang

Medivation’s Prostate Cancer Drug Approved by U.S. FDA

Medivation Inc., a biotechnology company whose shares have jumped sixfold in the past 12 months, won approval from U.S. regulators for a late-stage prostate cancer treatment.

Prostate Cancer Treatment Seen Drawing Medivation Bids: Real M&A

Medivation Inc., which has already quadrupled in a year, is still tempting acquirers with a prostate cancer treatment that’s poised to make it one of the world’s fastest-growing drug developers.

Pharmasset Falls on Rival Abbott Hepatitis C Therapy Results

Pharmasset Inc., developer of anti- viral medicines, plunged today after Abbott Laboratories said interim study results of its rival experimental hepatitis C therapy showed high cure rates.

Vertex Falls as Analyst Cuts Hep C Sales Estimate: Boston Mover

Vertex Pharmaceuticals Inc. fell the most in seven weeks after an analyst with Leerink Swann & Co. cut sales estimates for a hepatitis C pill made by the company that was approved by U.S. regulators last year.

Bristol-Myers, Gilead Seek AIDS Cocktail Success in Hepatitis C

Bristol-Myers Squibb Co. and Gilead Sciences Inc. , makers of the top-selling combination pills for AIDS, are trying to duplicate their success to combat another evasive virus, hepatitis C.

Onyx Drug Reduced Cancer in a Third of Patients With Myeloma in Study

Onyx Pharmaceuticals Inc.’s experimental drug carfilzomib shrank the tumors of one-third of study patients with multiple myeloma, a deadly blood cancer. The company’s shares surged the most in four months in New York trading.

`Warehoused' Hepatitis C Patients May Boost Merck, J&J

At Fred Poordad’s bustling hepatitis C clinic in the heart of Los Angeles, one in every five patients receives no treatment. They are waiting for a wave of new drugs, expected in the next 18 months, that may boost their chance at a cure by as much as 10-fold.

Roche Smart-Bomb Cancer Drug Delays Breast-Tumor Growth

An experimental breast cancer drug from Roche Holding AG that carries chemotherapy directly into malignant cells while bypassing healthy ones delayed tumors longer and with fewer side effects than an established therapy.

Intermune to Start European Sales of Lung Drug in September

Intermune Inc. , which won European approval Feb. 28 for Esbriet, will start selling the lung- disease drug in September in Germany and in other parts of Europe next year, Chief Executive Officer Dan Welch said.

Dendreon Cancer Drug Faces U.S. Review Tied to Its Sole Product

Dendreon Corp. is relying on a decision by Medicare to help generate $1.75 billion a year for the prostate cancer drug Provenge, the company’s only product.

"In light of recent development of interferon-free regimens and likely more aggressive development as a result of recent transactions in the space, we are further curtailing the Incivek tail."

- Howard Liang on Jan 30, 2012

New York

Food And Drug Administration

Boston

New Jersey

Death Toll Passes 90 After Oklahoma Tornado Hits Suburb

European Stocks Fall From 2008 High as Carnival Slides

Asia Stocks Fall From Five-Year High as ICBC Declines

WTI Crude Trades Near Seven-Week High as Stockpiles Seen Falling

Yen Slips as Amari Backtracks While Europe Shares Decline